Cabaletta Bio Inc

For the period ended Sep 30, 2024. Filed Nov 14, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 14, 2024

CABA$1.45-3.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share amounts)

	Common Stock
	Shares	Amount	AdditionalPaid-in Capital	Accumulated Other Comprehensive Income	Accumulated Deficit	TotalStockholders’ Equity
Balance—December 31, 2022	29,445,134	$—	$270,129	$(47)	$(165,562)	$104,520
Stock-based compensation	—	—	2,480	—	—	2,480
Net unrealized gains on available-for-sale securities	—	—	—	47	—	47
Issuance of common stock in connection with exercise of stock options	84,264	—	458	—	—	458
Issuance of common stock upon exercise of pre-funded warrants	1,811,591	—	—	—	—	—
Net loss	—	—	—	—	(15,854)	(15,854)
Balance—March 31, 2023	31,340,989	$—	$273,067	$—	$(181,416)	$91,651
Stock-based compensation	—	—	2,803	—	—	2,803
Issuance of common stock, net of issuance costs of $6,295	8,337,500	—	93,755	—	—	93,755
Issuance of common stock in connection with exercise of stock options	107,122	—	390	—	—	390
Issuance of common stock under employee stock purchase plan	8,071	—	32	—	—	32
Net unrealized losses on available-for-sale securities	—	—	—	(3)	—	(3)
Net loss	—	—	—	—	(14,487)	(14,487)
Balance—June 30, 2023	39,793,682	$—	$370,047	$(3)	$(195,903)	$174,141
Stock-based compensation	—	—	3,009	—	—	3,009
Net unrealized losses on available-for-sale securities	—	—	—	(18)	—	(18)
Issuance of common stock in connection with exercise of stock options	81,640	—	239	—	—	239
Issuance of common stock upon exercise of pre-funded warrants	1,784,847	—	—	—	—	—
Net loss	—	—	—	—	(16,448)	(16,448)
Balance—September 30, 2023	41,660,169	$—	$373,295	$(21)	$(212,351)	$160,923

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share amounts)

	Common Stock
	Shares	Amount	AdditionalPaid-in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	TotalStockholders’ Equity
Balance—December 31, 2023	47,823,232	$—	$469,396	$39	$(233,237)	$236,198
Issuance of common stock, net of issuance costs of $147	258,070	—	5,746	—	—	5,746
Stock-based compensation	—	—	3,791	—	—	3,791
Net unrealized losses on available-for-sale securities	—	—	—	(77)	—	(77)
Issuance of common stock in connection with exercise of stock options	167,813	—	1,109	—	—	1,109
Net loss	—	—	—	—	(25,047)	(25,047)
Balance—March 31, 2024	48,249,115	$—	$480,042	$(38)	$(258,284)	$221,720
Stock-based compensation	—	—	5,013	—	—	5,013
Issuance of common stock in connection with exercise of stock options	27,407	—	250	—	—	250
Issuance of common stock under employee stock purchase plan	14,947	—	129	—	—	129
Net unrealized gains on available-for-sale securities	—	—	—	9	—	9
Net loss	—	—	—	—	(27,602)	(27,602)
Balance—June 30, 2024	48,291,469	$—	$485,434	$(29)	$(285,886)	$199,519
Stock-based compensation	—	—	5,250	—	—	5,250
Issuance of common stock in connection with exercise of stock options	15,475	—	71	—	—	71
Issuance of common stock upon exercise of pre-funded warrants	543,479	—	—	—	—	—
Net unrealized gains on available-for-sale securities	—	—	—	30	—	30
Net loss	—	—	—	—	(30,629)	(30,629)
Balance—September 30, 2024	48,850,423	$—	$490,755	$1	$(316,515)	$174,241

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.